4,976 reports of this reaction
1.5% of all CETIRIZINE HYDROCHLORIDE ALLERGY reports
#19 most reported adverse reaction
JOINT SWELLING is the #19 most commonly reported adverse reaction for CETIRIZINE HYDROCHLORIDE ALLERGY, manufactured by Aurohealth LLC. There are 4,976 FDA adverse event reports linking CETIRIZINE HYDROCHLORIDE ALLERGY to JOINT SWELLING. This represents approximately 1.5% of all 341,924 adverse event reports for this drug.
Patients taking CETIRIZINE HYDROCHLORIDE ALLERGY who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is a less commonly reported adverse event for CETIRIZINE HYDROCHLORIDE ALLERGY, but still significant enough to appear in the safety profile.
In addition to joint swelling, the following adverse reactions have been reported for CETIRIZINE HYDROCHLORIDE ALLERGY:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 4,976 FDA reports for CETIRIZINE HYDROCHLORIDE ALLERGY. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 1.5% of all adverse event reports for CETIRIZINE HYDROCHLORIDE ALLERGY, making it a notable side effect.
If you experience joint swelling while taking CETIRIZINE HYDROCHLORIDE ALLERGY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.